Management of Hepatitis B Vaccine Non-Response

Understanding Hepatitis B Vaccine Non-Response

The Centers for Disease Control and Prevention defines non-response to hepatitis B vaccination as failure to develop protective antibody levels (anti-HBs ≥10 mIU/mL) after completing a standard vaccination series 1
Age is a known factor affecting immune response to hepatitis B vaccination, with older adults having lower seroconversion rates 2
The standard adult dose of Engerix-B is 20 μg (1.0 mL) per dose in a 3-dose schedule at 0, 1, and 6 months 3

For adults who failed the conventional hepatitis B vaccination schedule, a high-dose revaccination series with 40 μg of Engerix-B administered on a 0, 1, 2, and 6-month schedule is recommended by the American College of Physicians 2
The Centers for Disease Control and Prevention recommends using Heplisav-B (if available), which has demonstrated higher seroprotection rates (approximately 90%) compared to Engerix-B (70.5%-90.2%) in clinical trials 3
Heplisav-B is administered as a 2-dose series (0 and 1 month) with 20 μg (0.5 mL) per dose 2

The Infectious Diseases Society of America recommends testing for anti-HBs levels 1-2 months after completing the revaccination series to confirm seroprotection 4, 1
Seroprotection is defined as anti-HBs levels ≥10 mIU/mL by the Centers for Disease Control and Prevention 1
Individuals who develop protective antibody levels following vaccination are considered protected, even if antibody levels subsequently decline, according to the Centers for Disease Control and Prevention 1

The American College of Physicians states that one should not restart the series if the vaccination schedule is interrupted; simply continue where left off 2
Vaccine doses administered ≤4 days before the minimum interval are considered valid by the American College of Physicians 2
For older adults, the high-dose regimen is particularly important as age-related immune senescence can reduce vaccine response, according to the American College of Physicians 2

The Centers for Disease Control and Prevention recommends testing anti-HBs levels 1-2 months after the third dose to document non-response (anti-HBs <10 mIU/mL) 5
The Centers for Disease Control and Prevention suggests that individuals who fail to respond to the initial vaccine series should be revaccinated, with one approach being to administer a second complete 3-dose vaccine series if non-response persists after the first revaccination series 5

The American Academy of Family Physicians recommends that for occupational exposures in documented non-responders to one 3-dose series, 1 dose of HBIG plus restart a second 3-dose vaccine series should be given if the source is HBsAg-positive 6
The Centers for Disease Control and Prevention states that individuals who remain non-responsive after two complete 3-dose series (6 total doses) are considered true non-responders and should not receive additional vaccination, but rather require counseling about their susceptibility and the need for HBIG prophylaxis after any future hepatitis B exposures 5

The Centers for Disease Control and Prevention recommends testing anti-HBs levels 1-2 months after completing the revaccination series to confirm seroprotection (≥10 mIU/mL) 5